---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-24-000149"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:08:07.578859+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MacroGenics Q2 net loss $55.7M; receives $100M Incyte milestone

## Summary
- Net loss of $55.7M ($0.89 diluted EPS) vs net income of $57.5M in Q2 2023.
- Revenue of $10.8M, down from $13.1M YoY, driven by lower Provention revenue.
- Cash $140.4M at June 30; $100M Incyte milestone received post-quarter extends cash runway into 2026.
- TAMARACK Phase 2 mCRPC data (vobra duo) to be presented at ESMO in September 2024.
- MGC028 IND expected by end 2024; LORIKEET Phase 2 enrollment completion anticipated in 2024/early 2025.

## SEC filing metadata
- accession: 0001125345-24-000149
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000149/0001125345-24-000149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000149/mgnx-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-24-000149
- JSON: https://secwatch.observer/filing/0001125345-24-000149.json
- Plain text: https://secwatch.observer/filing/0001125345-24-000149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.